Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans

@article{Xie2017RiskOD,
  title={Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans},
  author={Yan Xie and Benjamin Bowe and Tingting Li and Hong Xian and Yan Yan and Ziyad Al-Aly},
  journal={BMJ Open},
  year={2017},
  volume={7}
}
OBJECTIVE Proton pump inhibitors (PPIs) are widely used, and their use is associated with increased risk of adverse events. [] Key MethodDESIGN Longitudinal observational cohort study. SETTING US Department of Veterans Affairs. PARTICIPANTS Primary cohort of new users of PPI or histamine H2 receptor antagonists (H2 blockers) (n=349 312); additional cohorts included PPI versus no PPI (n=3 288 092) and PPI versus no PPI and no H2 blockers (n=2 887 030). MAIN OUTCOME MEASURES Risk of death.
The mortality risk of Proton Pump Inhibitors in 1.9 Million US Seniors: an extended Cox survival analysis.
  • S. BaikK. FungC. McDonald
  • Medicine
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2021
The association between use of proton-pump inhibitors and excess mortality after kidney transplantation: A cohort study
TLDR
It is demonstrated that PPI use is associated with an increased mortality risk in KTRs, independent of potential confounders, and the data suggest that this risk is highest amongKTRs taking high PPI dosages.
Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study
TLDR
Taking PPIs is associated with a small excess of cause specific mortality including death due to cardiovascular disease, chronic kidney disease, and upper gastrointestinal cancer and Heightened vigilance in the use of PPI may be warranted.
Proton Pump Inhibitor Taking Associates with Higher All-Cause Mortality and CV Events in Peritoneal Dialysis Patients
TLDR
Clinicians need to be more careful when using PPI and need to master the indications more rigorously in patients receiving PD treatment to clarify the impact of PPI taking on mortality and adverse cardiovascular events in peritoneal dialysis patients.
No Associations Between Regular Use of Proton Pump Inhibitors and Risk of All-Cause and Cause-Specific Mortality: A Population-Based Cohort of 0.44 Million Participants
TLDR
Regular use of PPIs was not associated with an increased risk of all-cause and cause-specific mortality in a prospective analysis of 440,840 UK residents and 13,154 deaths.
Proton pump inhibitor usage is associated with higher all-cause mortality and CV events in peritoneal dialysis patients
TLDR
Clinicians are supposed to be more careful when using PPI and need to master the indications more rigorously in patients receiving peritoneal dialysis treatment.
Associations of Proton-Pump Inhibitors and H2 Receptor Antagonists with Chronic Kidney Disease: A Meta-Analysis
TLDR
This study demonstrates statistically significant 1.3-fold increased risks of CKD and ESRD in patients using PPIs, but not in Patients using H2RAs.
Association Between Proton Pump Inhibitors and Asthma: A Population-Based Cohort Study
TLDR
This population base study demonstrated that patients with long-duration of PPI use are at a higher risk of developing asthma, regardless of age, gender, comorbidities, and medications.
The association of proton pump inhibitors and chronic kidney disease: cause or confounding?
TLDR
The constellation of evidence suggests that PPI use is associated with increased risk of adverse kidney outcomes, and exercising vigilance in the use of PPI is warranted.
...
...

References

SHOWING 1-10 OF 64 REFERENCES
Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD.
TLDR
PPI exposure associates with increased risk of incident CKD, CKD progression, and ESRD, and a graded association between duration of PPI exposure and risk of renal outcomes among those exposed for ≤30 days is detected.
Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.
TLDR
Proton pump inhibitor use was associated with incident CKD in unadjusted analysis and in analysis adjusted for demographic, socioeconomic, and clinical variables and future research should evaluate whether limiting PPI use reduces the incidence of CKD.
Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis
TLDR
This study does not support the proposition of a pharmacological effect of gastric acid suppressors on the risk of HCAP and formed eight restricted cohorts of new users of NSAIDs, aged ≥40 years, using a common protocol in eight databases.
Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis.
TLDR
The avoidance of PPI medication may prevent the development of dementia and is supported by recent pharmacoepidemiological analyses on primary data and is in line with mouse models in which the use of PPIs increased the levels of β-amyloid in the brains of mice.
Proton pump inhibitors and hypomagnesemia in the general population: a population-based cohort study.
TLDR
Prolonged PPI use and concomitant loop diuretic use are associated with a stronger risk increase in the general population and similar but weaker associations were found in H2RA users, except for interaction withloop diuretics.
Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals.
TLDR
In older patients discharged from acute care hospitals, the use of high-dose PPIs is associated with increased 1-year mortality, and physicians need to use caution and balance benefits and harms in long-term prescription of high dose PPIs.
Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study.
TLDR
Those who started PPI therapy had an increased risk of acute kidney injury and acute interstitial nephritis, and these are potentially reversible conditions that may not be readily attributed to drug treatment.
Proton-pump inhibitors and risk of fractures: an update meta-analysis
TLDR
In this update meta-analysis of observational studies, PPI use modestly increased the risk of hip, spine, and any-site fracture, but no evidence of duration effect in subgroup analysis.
...
...